Kodiak Sciences
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 111
- Market Cap
- $138.9M
- Introduction
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
- Conditions
- Macular Edema Secondary to Inflammation
- Interventions
- Other: Sham Comparator
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 150
- Registration Number
- NCT06996080
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
- Conditions
- Macular Edema Secondary to Inflammation
- Interventions
- Other: Sham Comparator
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 150
- Registration Number
- NCT06990399
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 675
- Registration Number
- NCT06556368
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Retina Macula Institute of Arizona, Scottsdale, Arizona, United States
🇺🇸Retina Associates SW, Tucson, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
- Conditions
- Diabetic Retinopathy
- Interventions
- Other: Sham injection
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 255
- Registration Number
- NCT06270836
- Locations
- 🇺🇸
Retina Associates SW, Tucson, Arizona, United States
🇺🇸Global Research Management, Inc. - Lugene Eye Institute, Glendale, California, United States
🇺🇸Retina Consultants of Orange County, Fullerton, California, United States
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
- Conditions
- Non-proliferative Diabetic Retinopathy
- Interventions
- Other: Sham injection
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 253
- Registration Number
- NCT05066230
- Locations
- 🇺🇸
Charleston Neurosciences Institute, Beaufort, South Carolina, United States
🇺🇸Retina Specialists of Idaho, Boise, Idaho, United States
🇪🇸Hospital Universitario Miguel Servet, Zaragoza, Spain
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 557
- Registration Number
- NCT04964089
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Retina Consultants of Texas, Houston, Texas, United States
🇺🇸Medical Center Ophthalmology Associates, San Antonio, Texas, United States
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 460
- Registration Number
- NCT04611152
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸MidAtlantic Retina, Philadelphia, Pennsylvania, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 459
- Registration Number
- NCT04603937
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, Ohio, United States
🇫🇷CHRU Dijon Complexe Du Bocage, Dijon, Côte-d'Or, France
🇺🇸Retina Specialists of Idaho, Boise, Idaho, United States
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
- Conditions
- Macular EdemaRetinal Vein Occlusion
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 568
- Registration Number
- NCT04592419
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Vitreo Retinal Consultants and Surgeons, Wichita, Kansas, United States
🇺🇸Tennessee Retina PC, Nashville, Tennessee, United States
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
- Conditions
- Wet Macular Degeneration
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 559
- Registration Number
- NCT04049266
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, Ohio, United States
🇺🇸Medical Center Ophthalmology Associates, San Antonio, Texas, United States
🇺🇸Vitreoretinal Surgery PA, Edina, Minnesota, United States